Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Revenue growth above 20%EBITDA margin compressionResults View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.6%Reaction day

₹100.50

prior close

₹102.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+2.0% vs market

Pharmaceuticals peers, median of 148sector+0.4%+2.2% vs sector

On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+1.5

15m

+1.4

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.6+0.6+2.0+0.4+2.2

Next day

+5.0+0.5+4.5+0.3+4.6

+6.0+0.8+5.2+0.5+5.5

+6.0+1.2+4.8+1.0+5.0

+4.8+1.5+3.3+0.6+4.2

+8.6+1.6+7.0-0.1+8.7

+7.5+1.8+5.7+0.1+7.4

15d

+5.8+3.3+2.5+1.5+4.3

+3.3+3.1+0.2-1.2+4.5

-3.5+2.3-5.8+0.9-4.4

-12.9+0.2-13.1-1.6-11.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma Limited has submitted its financial results for the period ended March 31, 2025 to the stock exchange. This is a routine regulatory disclosure under SEBI's listing requirements. The headline does not include the actual revenue, profit, or other financial figures, so the specific performance numbers are not available in the provided text. Retail investors would need to view the full results PDF for detailed line items such as revenue, operating profit, net profit, and segment performance.

Likely market impact

Without access to the detailed numbers, the impact on share price or shareholders cannot be determined from this announcement alone. Investors should review the full results document and any accompanying auditor's report to assess actual performance.

By the numbersStandalone · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹198.1 Cr	₹163.9 Cr	+20.9%
Operating profit	₹15.88 Cr	₹16.90 Cr	−6.0%
Profit after tax	₹12.46 Cr	₹15.36 Cr	−18.9%
EBITDA margin	9.4%	11.7%	−2.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.